H. Grossman A. Denys Ravic

154 SCIENTIFIC SESSIONS September 9-12 | F-1509 In Vitro Antimicrobial Activity and In Vivo Efficacy in a Mouse Staphylococcal-Septicemia Model of Water-Soluble Tripropeptin C Analogs S. Hirosawa 1 , H. Hashizume 2 , Y. Kobayashi 1 , R. Watabe 1 , K. Inoue 2 , Y. Takahashi 2 , S. Harada 2 , S. Ohba 3 , T. Masuda 3 , R. Sawa 2 , Y. Takahashi 1 , T. Miyake 1 , A. Nomotoector 2 , M. Shibasaki 2 ; 1 Inst. of Microbial Chemistry, Hiyoshi, Kanagawa, Japan, 2 Inst. of Microbial Chemistry, Tokyo, Japan, 3 Inst. of Microbial Chemistry, Numazu, Shizuoka, Japan. F-1510 Antimicrobial Activity of Six Seachaid Pharmaceuticals In- vestigational Compounds Tested against Gram-Positive Strains

R. E. Mendes

1 , D. J. Biedenbach 1 , A. A. Watters 1 , R. N. Jones 1 , R. G. Sherrill 2 , K. D. James 2 ; 1 JMI Lab., N Liberty, IA, 2 Seachaid Pharmaceuti- cals, Durham, NC. F-1511 Antimicrobial Activity and Spectrum of a Seachaid Phar- maceuticals Investigational Compound SP2078 Tested against Gram-Positive Pathogens R. E. Mendes, P. R. Rhomberg, M. Konrardy, R. N. Jones; JMI Lab., N Liberty, IA. F-1512 Time-Kill and Post-Antibiotic-Effect Studies of a Seachaid Pharmaceuticals Investigational Compound SP2078 against Wildtype and Multidrug-Resistant Pathogens R. E. Mendes, P. R. Rhomberg, D. M. Johnson, BS - MT, R. N. Jones; JMI Lab., N Liberty, IA. F-1513 Exploring Triazoles as Antimicrobials against Methicillin- Resistant Staphylococcus aureus MRSA

M. O. Abreu

1,2 , B. L. A. Ferreira 2 , D. Gonzaga 3 , V. Ferreira 3 , H. C. Castro 2 , F. A. Alves 1 ; 1 Programa de Pós Graduação - HUAP, Rio de Janeiro, Brazil, 2 LABiEMOL - Inst. de Biologia, Rio de Janeiro, Brazil, 3 Inst. de Química, Rio de Janeiro, Brazil. F-1514 CNH365.396, a Novel Marine-Derived Compound with Potent Activity against Methicillin-Resistant Staphylococcus aureus MRSA

M. Hensler

1 , E. Soubih 1 , K. Jang 1 , W. Thienphrapa 1 , J. Locke 2 , M. Cun- ningham 2 , B. Kwan 2 , S. Nam 1 , C. Kauffman 1 , D. Beatty 1 , K. J. Shaw 2 , V. Nizet 1 , W. Fenical 1 ; 1 Univ. Calif., San Diego, CA, 2 Trius Therapeutics, San Diego, CA. F-1515 Antivirulence Agents against MRSA and Streptococcus pyo- genes M. Shoham, G. Yu, B. Truitt, M. Pesho, V. Khodaverdian, L. Bollinger, A. Nash, R. Viswananthan; Case Western Reserve Univ., Cleveland, OH. F-1516 Killing and Lysis of Staphylococcus aureus and other Staphylo- cocci by an Engineered Endolysin

A. C. Fluit

1 , S. van Marm 1 , F. Eichenseher 2 , M. J. Loessner 2 , F. Pietersma 3 , E. C. H. Boel 1 ; 1 Univ. Med. Ctr. Utrecht, Utrecht, Netherlands, 2 ETH Zu- rich, Switzerland, 3 Micreos BV, Wageningen, Netherlands. F-1517 Soluble High-Affinity T Cell Receptors for the Detection and Treatment of Superantigen-Mediated Staphylococcal aureus Diseases

A. S. Chervin

1 , D. M. Mattis 2 , N. Wang 2 , W. Salgado-Pabon 3 , A. R. Spaulding 3 , O. N. Chuang-Smith 4 , L. M. Breshears 4 , M. L. Peterson 4 , A. R. Horswill 3 , C. L. Quinn 1 , P. M. Schlievert 3,1 , D. M. Kranz 2,1 ; 1 ImmuVen, Inc., Champaign, IL, 2 Univ. of Illinois, Urbana, IL, 3 Univ. of Iowa, Iowa City, IA, 4 Univ. of Minnesota, Minneapolis, MN. F-1518 Novel Biopolymer SYN01 Wound Treatment Reduces MRSA Biofilms in a Partial Thickness Porcine Wound Model and Modu- lates the Production of IL-8 in Human Macrophages

S. M. Townsend

1 , S. N. Garbers 1 , C. Perez 1 , J. Gil 2 , J. Valdes 2 , C. P. Smith 1 , S. C. Davis 2 , S. M. Baker 1 , W. P. Wiesman 1 ; 1 Synedgen, Inc., Claremont, CA, 2 Univ. of Miami, Miami, FL. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 177 F Poster Session Novel Antimicrobial Approaches and Agents Tuesday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: F-1519 Activity of HPi1, a Novel Quinoxaline, against Enterotoxigenic Bacteroides fragilis A. Hachmann, M. LaFleur, K. Lewis; Northeastern Univ., Boston, MA. F-1520 In Vitro Activity of Sodium Oxychlorosene against Multi- drug-Resistant MDR Pathogens

A. H. Stock

1 , S. S. Utley 1 , S. C. Cheatham 1 , M. R. Fleming 2 , D. W. Smith 3 , M. F. Wack 4 , M. B. Kays 5 ; 1 St. Francis Hlth., Indianapolis, IN, 2 Method- ist Dallas Med. Ctr., Dallas, TX, 3 Indiana Univ. Hlth. Methodist Hosp., Indianapolis, IN, 4 Indiana Univ. Methodist Hosp., Indianapolis, IN, 5 Purdue Univ., Indianapolis, IN. F-1521 Anti-Staphylococcal and Anti-Enterococcal Activity of Novel Protein Synthesis Inhibitors from the RX-04 Program J. M. Remy 1 , J. A. DeVito 1 , E. M. Duffy 1 , D. F. Sahm 2 ; 1 Rib-X Pharma- ceuticals, Inc., New Haven, CT, 2 Eurofins Medinet, Chantilly, VA. F-1522 Antibacterial Activity of Novel RX-04 Compounds against Biodefense Pathogens J. Hershfield 1 , L. Miller 1 , S. Halasohoris, N.A. 1 , C. Marchand, DVM 1 , J. Remy 2 , M. Leggio 2 , J. DeVito 2 , A. Marra 2 , A. Bhattacharjee 2 , Z. Kanyo 2 , E. Duffy 2 ; 1 USAMRIID, Fort Detrick, 2 Rib-X Pharmaceuticals, Inc., New Haven, CT. F-1523 Novel Ribosome Inhibitors are Efficacious in a Murine Respi- ratory Tract Infection Model Caused by Streptococcus pneumoniae A. Rey 1 , C. DelGorge 1 , A. Marra 2 , E. Bortolon 2 , D. Molstad 2 , E. Duffy 2 ; 1 Sanofi Pharmaceuticals, Toulouse, France, 2 Rib-X Pharmaceuticals, New Haven, CT. F-1524 In Vitro Activity of E-101, a Rapidly Bactericidal Myeloper- oxidase MPO-Based Agent, against Key Bacterial Pathogens

J. Deane

1 , A. Simenauer 1 , G. A. Denys 2 , P. O’Hanley 3 , J. T. Stephens 3 , D. F. Sahm 1 ; 1 Eurofins, Chantilly, VA, 2 Indiana Univ. Hlth. Path Lab, Indianapo- lis, IN, 3 Exoxemis, Inc., Little Rock, AR. F-1525 TP-271 is a Potent, Broad-Spectrum Fluorocycline with Activity against Community-Acquired Bacterial Respiratory and Biothreat Pathogens

T. H. Grossman

1 , C. Fyfe 1 , W. O’ Brien 1 , M. Hackel 2 , J. A. Sutcliffe 1 ; 1 Tetraphase Pharmaceuticals, Watertown, MA, 2 IHMA, Schaumburg, IL. F-1526 Novel 8-Heterocycle Substituted Tetracyclines are Potent and Broad Spectrum Antibacterial Agents with Oral Bioavailability X. Xiao, Y. Deng, C. Sun, C. Chen, D. Hunt, R. Clark, C. Fyfe, W. O’Brien, T. Grossman, J. Sutcliffe; Tetraphase Pharmaceuticals, Watertown, MA. 155 TUESDAY SCIENTIFIC SESSIONS Final Program F-1527 In Vitro Synergy Studies with a Promising New Compound, the Tetra- para-Guanidinoethylcalix[4]arene M. Grare 1 , M. Mourer 1 , J. Regnouf-de-Vains 1 , R. E. Duval 1,2 ; 1 UMR 7565, Univ. de Lorraine CNRS, Nancy, France, 2 ABC Platform, Nancy, France. F-1528 In Vitro Activity of C-101 Solution, a New Eosinophil Peroxi- dase EPO Containing Enzyme System against Gram-Negative and Gram-Positive Pathogens

G. A. Denys

1 , D. Shah 2 , D. F. Sahm 2 , R. C. Allen 3 , P. O’Hanley 4 , J. T. Stephens 4 ; 1 Indiana Univ. Hlth., Indianapolis, IN, 2 Eurofins, Chantilly, VA, 3 Creighton Univ. Med. Ctr., Omaha, NE, 4 Exoxemis, Inc., Little Rock, AR. F-1529 Identification of a Novel Anti-PcrV Antibody That Blocks Type Three Secretion and Provides Superior Protection in Pseudo- monas aeruginosa Animal Infection Models P. Warrener, R. Varkey, J. Zha, A. DiGiandomenico, M. Camara, P. Chow- dury, B. Sellman, K. Stover; MedImmune LLC, Gaithersburg. F-1530 Disposition of MGB-BP-3, a New Class of Antibacterial Agent, after Oral Administration in a Hamster Model of Severe Clostridium difficile Associated Diarrhoea CDAD

M. Ravic

1 , C. Suckling 2 , I. Hunter 2 , C. Gemmell 3 , P. Warn 4 , A. Sattar 4 , M. Saunders 5 ; 1 MGB Biopharma, Glasgow, United Kingdom, 2 Univ. of Strathclyde, Glasgow, United Kingdom, 3 Univ. of Glasgow and Strathclyde, Glasgow, United Kingdom, 4 Euprotec, Manchester, United Kingdom, 5 Kue- cept, Potters Bar, United Kingdom. F-1531 SRI-011225, a First-in-Class Bactericidal Antimicrobial Active against Drug-Resistant Pathogens L. Jong, K. Mortelmans, C. Green, L. Hokama, T. Tran, D. Sahner; SRI Intl., Menlo Park, CA.